n=406
270 weeks (114+156 weeks open label with SGLT2i!)
➡️Carefully selected population for nil significant cardio/cerebro-vascular or hepatic disease
➡️On MLD/50% MLD of RAASi
➡️1:1 randomisation
➡️Stratification as per eGFR & proteinuria
➡️MMRM statistics
Welcome to #TenTweetNephJC for a short recap! Nephrologists warned of renalism neglecting cardiac ischemia in kidney pts. ISCHEMIA-CKD dashed hopes. Waiting for a deceased donor kidney transplant in the US is a grueling journey for +100K pts with advanced chronic kidney disease
2/10
What did I miss?
🌤️Retrospective study: asymptomatic kidney transplant candidates tested for coronary heart disease (CHD) vs non-tested pubmed.ncbi.nlm.nih.gov/36595271/
Aim: to determine the effect of CHD testing on the risk of death or acute MI within 30 days after transplant
3/10
1 tweet methods
⏪ Retrospective cohort study, USRDS, 2000-2014
✅ 79334 Adults, 1st time kidney transplant
✅ CHD testing 12 months before transplant
🛠️ Instrumental analysis variable - less biased by confounding than standard methods @Husamjz
Would a new drug option for resistant hypertension get you excited? How about a superior trial design?
Time to learn about PRECISION - our twitter journal club had 720 tweets, but you can catch the highlights quickly with the regular #TenTweetNephJC thread👇
2/10
What did I miss?
We know we miss targeting many pathways that contribute to resistant hypertension, a condition with high cardiovascular morbidity.
Enter aprocitentan, a dual endothelin receptor antagonist, for it’s crack at a Phase 3 trial.
👉 where we catch you up on the week's #NephJC chat in 10 tweets
The topic at hand was Plasma Exchange and Vasculitis: the infamous debate of to PLEX or not to PLEX in AAV
Check out this thread to see if you change your mind on this comPLEX topic 👇
What did I miss?
PLEX, with its plausible biological rationale, has been in the center of debate for management of AAV since the 1980s, with several RCTs in favor of PLEX or against it
🔸️An updated meta-analysis which included the PEXIVAS results was discussed
1 tweet methods
✅ updated systematic review & meta-analysis
✅ RCTs of patients with AAV or pauci-immune RPGN receiving PLEX and ≥12mo. follow-up
✅ Outcome measures were at least one of: mortality, ESKD, serious infection, relapse, AE or health-related QoL
✳️ Welcome to #TenTweetNephJC, where we catch you up on the week's #NephJC chat in 10 tweets ✳️
The topic at hand was diuretic resistance, specifically compensatory post-diuretic sodium reabsorption (CPDSR). Let’s walk you through how it all flowed 💧
What did I miss?
We teach medical students that diuretic resistance occurs in large part due to CPDSR. While this has been validated in healthy individuals, does this hold true in patients w/ acute decomp heart failure (ADHF)?
Enter the study in question pubmed.ncbi.nlm.nih.gov/34529781/
1 tweet methods
✅Single center, prospective, observational study, with a randomized sub-cohort
✅Evaluating mechanisms of diuretic resistance in patients with ADHF on IV loops 💉
✅Supervised urine collection pre and post diuresis
✅Primary outcome = level of CPDSR